Additionally, Abdelfatah et al. found that NSCLC patients (n = 29) treated with pembrolizumab/atezolizumab combined with chemotherapy, who showed a ≥ 10% increase in CX3CR1+CD8+T cells post-treatment, had better ORR, PFS, and OS [93]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.